Abstract: The present application relates to treatment of a hematological disease selected from leukemia, lymphoma, and multiple myeloma in a patient in need thereof, comprising administering to the patient: (a) a therapeutically effective amount of a selective JAK1 inhibitor; (b) a therapeutically effective amount of an immunomodulatory agent, and (c) a therapeutically effective amount of a steroid.

Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.

Abstract: The present invention provides diagnostic and therapeutic methods for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising an inhibitor of H3K27 methylation, methods of predicting responsiveness of a patient having a cancer to treatment comprising one or more inhibitors of H3K27 methylation, methods of selecting a therapy for a patient having a cancer, and methods of treating cancer based on expression levels of biomarkers of the invention (e.g., the expression level of SIV1ARCA2 or the occupancy level of H3K27 at a SMARCA2 promoter).

Abstract: Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: A method of treating a subject suffering from epilepsy includes administering an effective amount of a cholecystokinin-2 receptor antagonist or a pharmaceutical acceptable salt thereof to the subject. A pharmaceutical composition includes the cholecystokinin-2 receptor antagonist or a pharmaceutical acceptable salt thereof as active ingredient, one or more antiepileptic compounds, and a pharmaceutically acceptable excipient.

Abstract: The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and —B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.

Abstract: The present invention relates to the use SHIP inhibitors to induce expression of granulocyte colony stimulating factor (G-CSF) in a subject, thereby promoting expansion of hematopoietic and mesenchymal stem cells. The present invention generally relates to new uses of SHIP inhibitors for therapeutic purposes. More particularly, the present invention relates to the use of SHIP inhibitors, including, without limitation, SHIP and/or pan-SHIP1/2 inhibitors, for the inhibition of SHIP to induce expression of granulocyte colony stimulating factor (G-CSF) to treat various-diseases or conditions.

Abstract: Formulations, kits and methods for effecting contraception are disclosed. These formulations, kits and methods involve the delivery of progestins and estrogens in amounts personalized to the body weight and or the BMI of the women receiving the treatment.

Abstract: Canine quality of life, as judged by playfulness and sociability, rapidly declines as a dog ages. Dehydroepiandrosterone Sulfate (DHEAS) is an androgen that opposes cortisol in the fight or flight response, and we have proposed that wolves with exceptionally high circulating levels of DHEAS were the ones that interacted with humans, initiating the process of domestication that led to canis familiaris familiaris, the dogs we know today. Primates, particularly humans, have extremely high levels of circulating DHEAS. We discovered that administering primate levels of DHEA to canines dramatically increases their quality of life, as judged by remarkable increases in their playfulness and sociability. This discovery appears poised to maintain canine “puppy-like” behavior throughout the canine lifespan.

Abstract: A method of treating an inflammatory or infectious disease includes administering an effective amount of pharmaceutical composition to a subject in need of treatment of the inflammatory or infectious disease. The composition includes an aqueous suspension of nanoparticles of a glucocorticosteroid compound.

Abstract: In one aspect, the disclosure relates to compositions of lithium cholesterol compositions, including but not limited to lithium cholesterol sulfate compositions which are useful as therapeutic agents. The disclosure also relates to methods of making lithium cholesterol compositions and pharmaceutical compositions comprising therapeutically effective amounts of the lithium cholesterol compositions. The present disclosure also includes methods of treating one or more clinical neurological conditions with the lithium cholesterol compositions, such as Alzheimer's disease, autism spectrum disorder, bipolar disorder, or other neuropsychiatric disorders.

Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of high blood pressure or low blood pressure and a variety of symptoms related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: A topical composition useful for treating psoriasis and other skin disorders.

Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.

Abstract: The present invention relates to systemic detoxification by using extracts of Withania somnifera (ashwagandha) and its Nrf2-activating components withaferin-A, 12-deoxywithastramonolide, and Quresimine A. When ingested, the transcription factor Nrf2, which is a crucial element in intracellular detoxification pathways, leads to elimination of potentially toxic compounds. In parallel, the expression of inflammatory cytokines is decreased. Therefore, the extract can be used to reduce the adverse effects of air pollution generally (and especially of particulate air pollution), which includes: cardiovascular problems, respiratory diseases, and chronic inflammation of tissues that come into contact with air borne particles.

Abstract: Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.

Abstract: The present invention relates to a pharmaceutical composition (nanosuspension) for long-acting injectable (LAI) drug for long-term supportive therapy of HIV/AIDS. A pharmaceutical nanosuspension to be used as an injectable drug for long-term supportive therapy of HIV infection comprising a composition containing, as an active ingredient, a compound of general formula 1 in a crystalline or polycrystalline form wherein is C2H5CON?Na+, NH2.

Abstract: Provided herein are 2?-fucosyllactose compounds and methods of using such for treating inflammatory bowel diseases (IBD) (e.g.

Abstract: There are provided compositions and methods for prevention or treatment of atherosclerosis and related disorders. More specifically, there are provided desmocollin 1 inhibitor compounds and pharmaceutical compositions thereof for use in the prevention or treatment of atherosclerosis and related disorders and/or for promotion of HDL biogenesis in a subject.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.

Abstract: Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters.

Abstract: Compositions and methods suitable for treating diseases and conditions associated excessive neuronal excitability, and/or diseases associated with gain-of-function mutations in KCNT1. More specifically, antisense oligonucleotides specific for KCNT1 and their use for treating diseases and conditions associated with excessive neuronal excitability and/or gain-of-function mutations of KCNT1.

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

Abstract: A heparin structure with increased anticoagulant activity and method of making the same are disclosed. A heparin sample is provided and treated with a heparan sulfate sulfotransferase in an enzymatic reaction to add sulfuryl groups from a sulfuryl group source to the heparin sample, resulting in a heparin structure having above about 8% more 3-O-sulfo groups relative to wild-type bovine intestinal heparin. The added sulfuryl groups modify the heparin structure and increase the sample's binding to antithrombin III and its anticoagulant activity to be more similar and a viable alternative to porcine intestinal heparin. The modified heparin exhibits an anti-FXa activity and an anti-FIIa activity greater than about 180 U/mg, and a ratio of the anti-FXa activity to the anti-FIIa activity of about 0.9 to about 1.1, consistent with U.S. Pharmacopeia (USP) heparin activity specifications.

Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.

Abstract: The present invention discloses a branched polyethylene glycol epoxy derivative crosslinked sodium hyaluronate gel, preparation and application thereof. The crosslinking agent used in the crosslinked sodium hyaluronate gel prepared by the present invention is a polyethylene glycol epoxy derivative, due to the existence of multiple ether bonds in the molecule of the crosslinking agent, there are more hydrogen bonds in the gel system; meanwhile, due to the particularity of the space structure of the branched polyethylene glycol epoxy derivative, the gel prepared has a more complex winding structure in its space, thus achieving better stability. Moreover, the branched polyethylene glycol epoxy derivative involved in the present invention is a compound with single molecular weight, therefore, the gel prepared thereby has better batch stability.

Abstract: The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms.

Abstract: Compositions containing iron, glycine, and sulfate are provided.

Abstract: A method treating and/or preventing vascular calcification can include administering a mixed metal compound to a subject in need thereof.

Abstract: Copper-containing articles and methods for reducing, preventing or treating blepharitis, red eye, comprising having a subject in need thereof in proximity to or in contact with an article containing copper.

Abstract: The present invention relates to a composition based on components of natural origin, in particular ozonized olive oil “ and liquid vegetable extracts, for the topical treatment of vaginosis and/or vulvovaginitis of bacterial and/or fungal origin.

Abstract: The invention relates to a method for producing an osteoinductive calcium phosphate material, the method comprising the steps of providing a sintered calcium phosphate starting material having a surface topography consisting of calcium phosphate grains, subjecting the sintered calcium phosphate starting material to a hydrothermal treatment of between 125-150° C. for a duration sufficient to change calcium phosphate grains on the surface of the starting material into calcium phosphate needles.

Abstract: Methods and compositions for improving postoperative recovery are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing conditions associated with postoperative recovery.

Abstract: Methods and compositions for improving postoperative recovery are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing conditions associated with postoperative recovery.

Abstract: A method of producing helper T cells, comprising: (i) culturing T cells, which have been induced from pluripotent stem cells and into which a CD4 gene or a gene product thereof has been introduced, in a medium containing IL-2 and IL-15; and (ii) isolating CD40L-highly expressing T cells from cells obtained in step (i).

Abstract: Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.

Abstract: Provided herein are compositions of NK-92® cells that express a CD19 CAR, CD16 and IL2, and the method of using these cells to and treat cancer in a patient.

Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a co-stimulatory signaling region having a mutated form of a cytoplasmic domain of CD28 that enhances CAR-T cell function, e.g. by reducing CAR-T cell exhaustion. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a HLA-A3 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.

Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.

Abstract: Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using isolated populations of mesenchymal stem cells are disclosed.

Abstract: Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE2)-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE2-stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).

Abstract: The embodiments disclosed herein generally relate to systems, devices and methods for the fractionation, isolation, extraction and processing of the adipose supernatant layer of a bone marrow aspirate. In particular, the various embodiments relate to systems, devices, and methods of obtaining, utilizing, and processing the adipose supernatant layer of a bone marrow aspirate as a source of mesenchymal stem cells.

Abstract: The present invention relates to a method for the treatment of scleroderma through the delivery of matrix metalloproteinase (MMP) to a patient in need thereof, preferably under the control of a gene switch. In this manner, the use of a ligand activator to activate or deactivate the expression of MMP controls the gene switch. In another embodiment, the invention is directed to the delivery of autologous genetically modified cells transfected/transduced with a polynucleotide encoding MMP under the control of a gene switch activatable through the use of an activator ligand for the treatment or scleroderma.

Abstract: The present disclosure provides compositions composed of amniotic fluid and/or modified amniotic fluid, a pharmaceutically acceptable carrier, and optionally a placental tissue graft, micronized placental tissue components, or extracts derived therefrom. Also described are systems and apparatuses for administering or storing said compositions, as well as methods of treatment using said compositions.

Abstract: A method of preparation of a solution used for therapeutic and regenerative applications having a concentration of at least about 0.05 microgram of total protein extract is disclosed. The method includes collecting an umbilical cord, incubating the umbilical cord in a solution containing antibiotics for sterilization, washing the umbilical cord in a buffered salt solution, homogenizing the umbilical cord in the buffered salt solution so as to produce an aqueous solution, applying an ultrasonic processer to the aqueous solution to sonicate and disrupt umbilical cord tissue, placing the aqueous solution into a centrifuge to separate the aqueous solution into a soluble component and a non-soluble component, filtrating and discarding the non-soluble component of the aqueous solution from the centrifuge through a 0.2 micron filter, and measuring protein concentration of the soluble component to insure at least about 0.05 microgram of total protein extract.

Abstract: The present invention provides compositions and methods that promote wound healing. The invention provides a composition comprising an effective amount of a biopolymer, an antiseptic, an anti-inflammatory agent, and other agents.

Abstract: Provided herein are agents, compositions, and methods for agricultural use, e.g., for altering the level, activity, or metabolism of one or more microorganisms resident in a host nematode or arthropod (e.g., honeybee or silkworm), the alteration resulting in an increase in the fitness of the host. The invention features a composition that includes an agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is beneficial to the host. By promoting favorable microbial levels, microbial activity, microbial metabolism, and/or microbial diversity, the agents described herein may be used to increase the fitness of a variety of beneficial nematodes or arthropods, such as bees and silkworms, utilized in agriculture and commerce.

Abstract: Embodiments of the present disclosure relate to methods for ex vivo determining whether a patient with metastatic melanoma is likely to benefit from a treatment with an anti CTLA-4 molecule, preferably ipilimumab, by analyzing the gut microbiota in a fecal sample from said patient.